Gilead Sciences, Inc.

Gilead Pharmasset LLC

Scott D Schroeder

John O Link

Winston C Tse

Jennifer R Zhang

James G Taylor

Jeromy J Cottell

Michael Graupe

Eda Y Canales

Qi Liu

Michael L Mitchell

William John Watkins

Scott E Lazerwith

Elizabeth M Bacon

Randall Halcomb

Thorsten A Kirschberg

Chienhung Chou

Darryl Kato

Nathan E Wright

Hongyan Guo

Hyung-Jung Pyun

Sheila M Zipfel

Gediminas J Brizgys

Jiayao Li

Randall W Vivian

Richard L Mackman

Carina E Cannizzaro

Choung U Kim

Manoj C Desai

Aesop Cho

Lianhong Xu

Jay P Parrish

Hongtao Liu

Jianyu Sun

Gary Bruce Phillips

Zheng-Yu Yang

Musong Kim

Christopher T Clark

Lan Jiang

Hong Yang

Dimitrios Stefanidis

Elbert Chin

Devan Naduthambi

Kevin S Currie

Chandrasekar Venkataramani

Dustin S Siegel

Barton W Phillips

Hon Chung Hui

Michael O'Neil Hanrahan Clarke

Haolun Jin

Samuel E Metobo

Ryan McFadden

Michael R Mish

Julian Andrew Codelli

Chien-Hung Chou

Nathan D Shapiro

Qiaoyin Wu

Roland D Saito

Steven S Bondy

Yunfeng Eric Hu

Evan S Krygowski

Stephen E Ammann

James D Trenkle

Joseph H Saugier

Neil H Squires

Kirk L Stevens

Gayatri Balan

Hang Chu

Chao-I Hung

Weng K Chang

Daniel G Shore

Henok H Kinfe

Ana Zurisadai Gonzalez Buenrostro

Gregory F Chin

Rhiannon Thomas-Tran

Xiaochun Han

Chien-hung Chou

Suzanne M Szewczyk

Devleena M Shivakumar

James S Cassidy

Kavoos Kolahdouzan

Christopher J Swank

Joshua J Van Veldhuizen

Yasamin Moazami

Gregg M Schwarzwalder

Jason K Perry

Hai Yang

Mark J Bartlett

David W Lin

Julie Farand

Evangelos Aktoudianakis

Michael O Clarke

Terry Kellar

Jennifer Leigh Cosman

Bindu Goyal

Yafan Lu

Charles William Rowe

Doris T Tang

Ezra Roberts

Tezcan Guney

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

Sars-cov2 main protease inhibitors

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Therapeutic compounds for HIV virus infection

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, L, W, W, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

The present disclosure provides pyrimidine dione compounds of Formula I

CD73 compounds

SARS-COV2 main protease inhibitors

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

Capsid inhibitors for the treatment of HIV

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Thienopyrrole compounds

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Therapeutic compounds

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Cot modulators and methods of use thereof

The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.

Growing community of inventors

Union City, CA, United States of America

Scott D Schroeder